Astellas Pharma Canada pledges additional funding in support of Canadian
National Transplant Research Program
Goal is to improve patient health outcomes for organ and tissue transplant
MARKHAM, ON, July 3, 2013 /CNW/ - Astellas Pharma Canada, Inc. has announced a
new partnership with the recently launched Canadian National Transplant
Research Program (CNTRP), a novel research initiative that brings a
collaborative and transdisciplinary approach to advancing research and patient
care in the field of transplant.
Astellas has pledged $1 Million over a period of five years to support
Canadian investigators in the transplant field as they work to address
barriers to tissue and organ donation, with the ultimate goal of improving
long-term outcomes and quality of life for transplant patients.
The program is led byDr. Lori Westat the Alberta Transplant Institute,
University of Alberta, andDr. Marie-Josée Hébertat the Université de
Montréal. It brings together 105investigators and 86 collaborators from
13 different universities and research centres across Canada.
"By bringing the transplant research community together with industry, we will
be able to investigate barriers to improve the availability of transplants for
all patients who need them, to improve the safety of transplants so we can
have better long-term results and fewer complications, as well as to improve
the efficacy of transplants so we can improve the quality of life of patients
who have been transplanted," says Dr. Lori West, Director of the CNTRP and
Professor of Pediatrics, Surgery and Immunology at the University of
Alberta. "Industry engagement with the university-based academic researchers
of the CNTRP will be exceedingly helpful in guiding subsequent innovation by
engaging basic science and clinical researchers in the continuum of
discovery. Stronger bridging with industry will accelerate health outcome
improvements and create an environment for innovation, on which the CNTRP will
build commercial partnerships towards better health for Canadians."
The program has the potential to have a transformative effect on the field of
transplantation. The hope is not only to increase scientific knowledge to
improve current healthcare practices, but also to drive further research that
will ultimately translate into novel treatments and enhanced donation policies
for the future. The CNTRP is the first program in the world to unite and
integrate the solid organ transplant, bone marrow transplant and the donation
and critical care research communities together in a groundbreaking national
"Astellas has a proud history of supporting the Canadian transplant
community," says Michael Tremblay, President, Astellas Pharma Canada, Inc. "We
are pleased to be able to provide additional support for key research
activities that will ultimately lead to better outcomes for transplant
patients here in Canada, and beyond."
About the Canadian National Transplant Research Program (CNTRP)
The Canadian National Transplant Research Program (CNTRP) is anational
initiative designed to increase organ and tissue donation in Canada and
enhance the survival and quality of life of Canadians who receive transplants.
The research goals of the CNTRP:
-- Increase the availability of transplants
-- Extend the longevity of grafts
-- Improve the long-term survival and quality of life of
-- Develop and enhance the pool of researchers and clinicians in
the field of transplantation
-- Integrate and coordinate transplantation research nationwide
More information about CNTRP can be found at www.cntrp.ca.
About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical
company dedicated to improving the health of people around the world through
the provision of innovative and reliable pharmaceutical products. The
organization is committed to becoming a global category leader in focused
areas by combining outstanding R&D and marketing capabilities. In Canada,
Astellas has an intense commercial focus on five therapeutic areas - Urology,
Immunology, Infectious Disease, Dermatology and Oncology.
For more information about Astellas Pharma Canada, Inc., please visit the
corporate website: www.astellas.ca
(1 )Harper Government supports Canadian National Transplant Research Program.
Press release, dated April 22, 2013.
Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905)
Dr. Lori West Director, Canadian National Transplant Research Program (780)
SOURCE: Astellas Pharma Canada, Inc.
To view this news release in HTML formatting, please use the following URL:
CO: Astellas Pharma Canada, Inc.
NI: MTC HEA CHARITY
-0- Jul/03/2013 12:30 GMT
Press spacebar to pause and continue. Press esc to stop.